Prestige Consumer Healthcare Inc. (NYSE:PBH) Receives $85.25 Average PT from Analysts

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have been assigned an average rating of “Moderate Buy” from the four ratings firms that are currently covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $85.25.

A number of research firms have recently issued reports on PBH. Sidoti cut shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price for the company. in a research note on Monday, December 9th. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a research note on Monday, November 11th. StockNews.com upgraded Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a research note on Friday, January 24th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th.

Prestige Consumer Healthcare Stock Performance

PBH opened at $78.67 on Tuesday. Prestige Consumer Healthcare has a 1 year low of $60.00 and a 1 year high of $86.36. The company has a current ratio of 3.56, a quick ratio of 2.10 and a debt-to-equity ratio of 0.61. The stock has a market cap of $3.89 billion, a PE ratio of 19.14, a P/E/G ratio of 2.17 and a beta of 0.51. The stock’s 50 day simple moving average is $79.90 and its 200-day simple moving average is $75.08.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a return on equity of 12.23% and a net margin of 18.54%. The business’s revenue was down .9% on a year-over-year basis. During the same period last year, the business earned $1.07 earnings per share. Sell-side analysts forecast that Prestige Consumer Healthcare will post 4.46 EPS for the current year.

Insider Buying and Selling

In other Prestige Consumer Healthcare news, insider William P’pool sold 8,987 shares of the company’s stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the sale, the insider now owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Ronald M. Lombardi sold 10,875 shares of Prestige Consumer Healthcare stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $82.60, for a total transaction of $898,275.00. Following the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at approximately $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,810 shares of company stock worth $3,187,300 over the last three months. 1.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. lifted its stake in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC grew its position in Prestige Consumer Healthcare by 200.0% in the third quarter. nVerses Capital LLC now owns 600 shares of the company’s stock valued at $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank increased its stake in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the last quarter. International Assets Investment Management LLC raised its holdings in Prestige Consumer Healthcare by 7,112.5% during the third quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after acquiring an additional 1,138 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Prestige Consumer Healthcare by 49.9% in the 3rd quarter. GAMMA Investing LLC now owns 1,163 shares of the company’s stock valued at $84,000 after buying an additional 387 shares during the last quarter. Institutional investors and hedge funds own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.